FDA Approves New HIV Drug For Marketing

FDA on Friday announced that etravirine tablets have been for marketing as a treatment for HIV infection in adults, approved following a priority review. The drug, which will be marketed by Tibotec Therapeutics Corporation as Intelence, is for adult patients with HIV infections who have failed treatment using other available antiretrovirals. Etravirine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) designed to help block an enzyme that HIV uses to multiply.

More: continued here

Filed under: Pharma Industry on January 29th, 2008